ClinicalTrials.gg
CompletedNCT01594346Updated May 9, 2012

Multicenter Vitamin E Trial in Aging Persons With Down Syndrome

A Phase 3 interventional study of Alpha-Tocopherol and Sugar Pill in Alzheimer's Disease and Down Syndrome, sponsored by New York State Institute for Basic Research. Completed. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2012-05-09.

Sponsored by New York State Institute for Basic Research · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
349
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the safety and effectiveness of 2,000 international units of Vitamin E (alpha tocopherol)on cognitive function of aging persons with Down syndrome. It is a randomized, double-blind, placebo-controlled trial lasting 36 months. It is expected that Vitamin E will slow the deterioration in cognitive functions associated with Alzheimer disease.

Read the detailed description

Alzheimer disease (AD) continues to be the most serious health problem faced by aging persons with Down syndrome. AD is also a major public health concern in the aging general population. With increasing life expectancy there will be a dramatic increase in the prevalence of AD cases, which will pose a significant increased burden on the health care system and individual providers of care. Persons with Down syndrome are uniquely vulnerable to a form of Alzheimer disease indistinguishable from the sporadic variety that affects aging individuals from the general population. Oxidative damage is a highly plausible mechanism in the pathogenesis of this disease due to the overexpression of superoxide dismutase, associated with a gene located on chromosome 21, which is present in triplicate in the Down syndrome genotype. For the last six years, we have been conducting a clinical trial to determine the safety and efficacy of the anti-oxidant Vitamin E in slowing the cognitive and functional decline associated with the dementia of AD among individuals with DS. The study is a randomized, double-blind trial, stratified in a two-arm parallel design. The subjects are medically stable individuals who are 50 years of age or older at the time of screening. Among those randomized to the treatment arm, vitamin E is taken in the form of 1000 IU capsules for 36 months. Each subject is evaluated every 6 months for 3 years. The primary outcome is is the Brief Praxis Test (BPT), which is well-suited to quantifying cognitive decline in this population. The target enrollment of 350 persons is estimated to be sufficient to provide adequate statistical power to detect a slowing by one-third in the rate of cognitive decline with vitamin E treatment. The Data and Safety Monitoring Board (DSMB) for this trial includes 4 physicians, and a statistician with expertise in clinical trials. Each DSMB member receives a report on each serious adverse event (SAE) on a flow basis, and statistically summaries of unblinded safety data--including deaths, adverse events and vital signs--prior to each meeting of the DSMB. The most recent DSMB meeting took place on February 23,2010. The timeline for study completion is: recruitment of the study sample (N=350) was completed on 12/31/2008; the final 36-month evaluation will take place in 04/2010; statistical analysis and final report of results is expected to be completed by 12/31/2010.

02

Conditions studied

  • Alzheimer's Disease
  • Down Syndrome

Keywords

  • Vitamin E
  • alpha-tocopherol
  • cognitive decline
  • Down syndrome
  • Aging
  • Dementia
03

In context

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

This study's enrollment of 349 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

New York State Institute for Basic Research is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • presence of clinically determined Down syndrome (karyotypes optional)
  • appropriately signed and witnessed consent form
  • age of 50 years or older at the start of the protocol
  • medically stable
  • medications stable more than 1 month
  • involvement/cooperation of informant/caregiver

Exclusion criteria

Exclusion Criteria:

  • medical/neurological condition (other than Alzheimer disease) associated with dementia
  • inability to adequately perform the Brief Praxis Test, as demonstrated by a score \<20
  • in the presence of dementia, modified Hachinski score > 4 at Screening Visit
  • major depression within 3 months
  • history of coagulopathy (inherited or acquired)
  • current use of anticoagulants
  • use of experimental medications within 2 months
  • regular use of vitamin E greater than 50 units per day during the previous 6 months
  • allergy to vitamin E
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
349 participants (actual)

Study arms

  • Placebo comparator
    Sugar Pill

    Drug: Sugar Pill

  • Active comparator
    Alpha-Tocopherol

    Drug: Alpha-Tocopherol

Interventions

  • 1,000 International Units, two times a day for 36 months

    Also known as: Vitamin E

  • DrugSugar Pill
06

What researchers measure

Primary outcomes

  1. The Brief Praxis Test

    Time frame: 36 months

Secondary outcomes

  1. The Fuld Object Memory Test

    Time frame: 36 Months

  2. New Dot Test

    Time frame: 36 Months

  3. Orientation Test

    Time frame: 36 Months

  4. Vocabulary Test

    Time frame: 36 Months

  5. Behavior and Function

    Time frame: 36 Months

  6. Clinical Global Impression

    Time frame: 36 Months

  7. Incident Dementia

    Time frame: 36 Months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2000, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2012
First posted
May 9, 2012
Start
Sep 2000
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
May 9, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01594346
Lead sponsor
New York State Institute for Basic Research
Responsible party
Arthur Dalton (Deputy Director, New York State Institute for Basic Research) — Principal investigator
First posted
May 9, 2012
Start date
Sep 2000
Primary completion
Apr 2010
Completion
Apr 2010
Last update
May 9, 2012

Study contacts

Paul S. Aisen, M.D.
study director · University of California, San Diego
Mary C. Sano, Ph.D.
study director · Bronx Veterans Medical Research Foundation
Howard F. Andrews, Ph.D.
study director · New York Psychiatric Institute
Wei-Yann Tsai, Ph.D.
study director · Columbia University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-Tocopherol

Start the discussion